Guardant Health introduces new epigenomic applications providing deeper insights for treatment selection with Guardant360(R) Liquid. Key Takeaway: Guardant Health has launched new applications for its Guardant360(R) Liquid, enhancing oncologists' ability to assess cancer treatment responses without traditional biomarkers. The new features include two epigenomic predictors aimed at identifying patients who could benefit from selective estrogen receptor degraders (SERDs) in advanced breast cancer. This development marks a significant advancement in precision oncology. Market sentiment analysis. Positive factors. * New applications enhance treatment selection insights. * Two novel epigenomic predictors introduced. * Focus on advanced breast cancer treatment. PALO ALTO, Calif.-(BUSINESS WIRE)-Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new applications for Guardant360(R) Liquid designed to help oncologists understand how a patient's cancer may respond to treatment in the absence of traditional biomarkers. The expanded capabilities include five key advances: Two novel epigenomic predictors identify patients that may benefit from selective estrogen receptor degraders (SERDs) in advanced breast cancer and i Frequently asked questions. What is Guardant360(R) Liquid? Guardant360(R) Liquid is a precision oncology tool for assessing cancer treatment responses. What new features were introduced? Two novel epigenomic predictors were added to enhance treatment selection insights. Who benefits from the new predictors? Patients with advanced breast cancer may benefit from selective estrogen receptor degraders. How does this impact oncologists? It helps oncologists understand treatment responses without relying on traditional biomarkers.

Guardant Health (Nasdaq: GH) said its Guardant360 Tissue test has received Laboratory Developed Tests and Services approval from Taiwan's Ministry of Health and Welfare (MOHW). The approval opens a path to reimbursement, and copayment for the test will roll out gradually across major hospitals in Taiwan. The test analyses more than 740 DNA genes and 367 RNA genes, along with tumour mutational burden, microsatellite instability and methylation-based features. Guardant says it is the first approved test in Taiwan to include both genomic and epigenomic insights. The company says the test needs 40% fewer slides and 92% less tissue surface area than industry standards. Guardant360, its blood test, won MOHW approval in 2024.

Guardant Health reported third-quarter 2026 revenue of $361 million, up 36.1% year on year and ahead of analyst estimates of $350.8 million. Its adjusted loss of $0.29 per share beat the consensus of a $0.31 loss. The diagnostics company raised its full-year revenue guidance to $1.37 billion at the midpoint, from $1.35 billion. Shield cancer screening test volumes rose 246%, helped by wider insurance coverage, including UnitedHealthcare, Carelon, and eviCore. Shield's cost per test fell 20% sequentially. Shares still fell, to $137.26 from $153.43 before the results, as investors weighed an operating margin of -36.8%. Management aims for cash flow breakeven by the end of 2027.